The parity paradigm: Can legislation help reduce the cost burden of oral anticancer medications?

Value in Health

Volumn 19, Issue 1, 2016, Pages 88-98

  Kircher, Sheetal M ^a   Meeker, Caitlin R ^b   Nimeiri, Halla ^a   Geynisman, Daniel M ^b   Zafar, S Yousuf ^c   Shankaran, Veena ^d   De Souza, Jonas ^e   Wong, Yu Ning ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d USA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

drug costs; neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; DRUG COST; DRUG PARITY LAW; HEALTH CARE POLICY; HUMAN; LAW; ONCOLOGY; PRIORITY JOURNAL; REVIEW; COST; ECONOMICS; FEE; HEALTH CARE COST; HEALTH INSURANCE; INSURANCE; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

ANTINEOPLASTIC AGENTS; COST SHARING; FEES, PHARMACEUTICAL; HEALTH EXPENDITURES; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; PATIENT PROTECTION AND AFFORDABLE CARE ACT; UNITED STATES;

EID: 84957839682     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.10.005     Document Type: Article

References (73)

1. E. Van Cutsem, C. Twelves, J. Cassidy, and et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 2001 4097 4106
2. B.J. Druker, M. Talpaz, D.J. Resta, and et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
3. M. Paley, N. Love, R. Carlson, and et al. Preferences for oral and parenteral antitumor therapy: a survey of 260 patients with metastatic breast cancer J Clin Oncol 23 Suppl. 2005 16
4. G. Liu, E. Franssen, M.I. Fitch, and et al. Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
5. S. Schott, A. Schneeweiss, J. Reinhardt, and et al. Acceptance of oral chemotherapy in breast cancer patients - a survey study BMC Cancer 11 2011 129
6. C. Twelves, M. Boyer, M. Findlay, and et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma Eur J Cancer 37 2001 597 604
7. S.B. Streeter, L. Schwartzberg, N. Husain, and et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions Am J Manag Care 17 Suppl. 5. 2011 SP38 SP44
8. A.H. Lebovits, J.J. Strain, S.J. Schleifer, and et al. Patient noncompliance with self-administered chemotherapy Cancer 65 1990 17 22
9. A.H. Partridge, J. Avorn, P.S. Wang, and et al. Adherence to therapy with oral antineoplastic agents J Natl Cancer Inst 94 2002 652 661
10. A.H. Partridge, L. Archer, A.B. Kornblith, and et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104 J Clin Oncol 28 2010 2418 2422
11. V. Regnier Denois, J. Poirson, A. Nourissat, and et al. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists Eur J Cancer Care 20 2011 520 527
12. Centers for Medicare and Medicaid. Prescription drugs (outpatient) limited coverage. Available from: http://www.medicare.gov/coverage/prescription-drugs-outpatient-limited-coverage.html. [Accessed May 11, 2015].
13. United States Census Bureau. Health insurance coverage in the United States: 2013. Available from: http://www.census.gov/content/dam/Census/library/publications/2014/demo/p60-250.pdf. [Accessed January 4, 2014].
14. Berndt ER, McGuire T, Newhouse JP. A primer on the economics of prescription pharmaceutical pricing in health insurance markets. National Bureau of Economic Research Working Paper. March 2011. Available from: http://www.nber.org/papers/w16879.pdf. [Accessed May 7, 2015].
15. USA Today/Kaiser Family Foundation/Harvard School of Public Health National Survey of Households Affected by Cancer. Available from: http://www.kff.org/kaiserpolls/pomr112006pkg.cfm. [Accessed May 7, 2015].
16. Y. Zafar, M. Goetzinger, R. Fowler, and et al. Impact of out-of-pocket expenses on cancer care J Clin Oncol 29 Suppl. 2011 abstr6006
17. Y. Bao, and R. Sturm The effects of state mental health parity legislation on perceived quality of insurance coverage, perceived access to care, and use of mental health specialty care Health Serv Res 39 2004 1361 1377
18. Mental Health Parity and Addiction Equity Act of 2008, Pub. L. No. 110-343 (2008).
19. Patient Protection and Affordable Care Act. Public Law 111-148, 42 USC 256a-1, § 1302, March 31, 2010.
20. Patient Protection and Affordable Care Act. Public Law 111-148, 29 USC § 1185a, March 31, 2010.
21. HR 2078, 51st Leg, 2nd Sess (AZ 2014). Available from: http://legiscan.com/AZ/bill/HB2078/2014. [Accessed August 18, 2014].
22. HB 265, 146th Leg (DE 2012). Available from: http://legis.delaware.gov/lis/lis146.nsf/vwlegislation/2959D68A872782FF8525794300716D42. [Accessed August 18, 2014].
23. SB 437, 116th General Assembly (IN 2009). Available from: http://www.in.gov/legislative/bills/2009/SE/SE0437.1.html. [Accessed August 18, 2014].
24. HB693, Regular Session (LA 2012). Available from: http://legiscan.com/LA/bill/HB693/2012. [Accessed August 18, 2014].
25. LD 627, 126th Leg, Second Regular Session (ME 2014). Available from: http://www.mainelegislature.org/legis/bills/display-ps.asp?LD=627&snum=126. [Accessed August 18, 2014].
26. SB 1761, 86th Leg (MN 2009-2010). Available from: https://http://www.revisor.mn.gov/bin/bldbill.php?bill=S1761.4.html&session=ls86. [Accessed August 18, 2014].
27. LB882, 102nd Leg (NE 2012). Available from: http://nebraskalegislature.gov/FloorDocs/102/PDF/Intro/LB882.pdf. [Accessed August 18, 2014].
28. SB 1834, 2014th Leg (NJ 2011). Available from: http://legiscan.com/NJ/text/S1834/id/43073. [Accessed August 18, 2014].
29. AB219, Regular session (CA 2013-2014). Available from: http://legiscan.com/CA/bill/AB219/2013. [Accessed January 2, 2015].
30. HB 1202, Regular session (CO 2010). Available from: http://legiscan.com/CO/bill/HB1202/2010. [Accessed January 2, 2015].
31. SB 50, Regular session (CT 2010). Available from: http://legiscan.com/CT/bill/SB00050/2010. [Accessed January 2, 2015].
32. HB 1159, Regular session (FL 2013). Available from: http://legiscan.com/FL/bill/H1159/2013. [Accessed January 2, 2015].
33. HB 943, Regular session (GA 2013-2014). Available from: http://legiscan.com/GA/bill/HB943/2013. [Accessed January 2, 2015].
34. HB 1964. Regular session (HI 2012). Available from: http://legiscan.com/HI/bill/HB1964/2012. [Accessed January 2, 2015].
35. HB 1825, 97th General Assembly (IL 2011-2012). Available from: http://legiscan.com/IL/bill/HB1825/2011. [Accessed January 2, 2015].
36. SB 179, Regular session (MD 2012). Available from: http://legiscan.com/MD/bill/SB179/2012. [Accessed January 2, 2015].
37. S2363, 187th General Assembly (MA 2011-2012). Available from: http://legiscan.com/MA/bill/S2363/2011. [Accessed January 2, 2015].
38. SB668, Regular session (MO 2014). Available from: http://legiscan.com/MO/bill/SB668/2014. [Accessed January 2, 2015].
39. SB 266, 77th Leg (NV 2013). Available from: http://legiscan.com/NV/bill/SB266/2013. [Accessed January 2, 2015].
40. SB 385, Regular session (NM 2011). Available from: http://legiscan.com/NM/bill/SB385/2011. [Accessed January 2, 2015].
41. SB 3988, Regular session (NY 2011-2012). Available from: http://legiscan.com/NY/bill/S03988/2011. [Accessed January 2, 2015].
42. SB 99, 130th General Assembly (OH 2013-2014). Available from: http://legiscan.com/OH/bill/SB99/2013. [Accessed January 2, 2015].
43. SB 765, Regular session (OK 2014). Available from: http://legiscan.com/OK/bill/SB765/2014. [Accessed January 2, 2015].
44. SB 428, Regular session (FI 2013). Available from: http://legiscan.com/RI/bill/S0428/2013. [Accessed January 2, 2015].
45. SB 189, Regular session (UT 2013). Available from: http://legiscan.com/UT/text/SB0189/2013. [Accessed January 2, 2015].
46. SB 450, Regular session (VA 2012). Available from: http://legiscan.com/VA/bill/SB450/2012. [Accessed January 2, 2015].
47. HB 1517, Regular session (WA 2011-2012). Available from: http://legiscan.com/WA/bill/HB1517/2011. [Accessed January 2, 2015].
48. SB 300, Regular session (WI 2013-2014). Available from: http://legiscan.com/WI/bill/SB300/2013. [Accessed January 2, 2015].
49. SB 62. Regular session (WY 2015). Available from: http://legiscan.com/WY/bill/SF0062/2015. [Accessed August 6, 2015].
50. Cancer Drug Coverage Parity Act of 2009, H.R. 2366, 111th Congress (2009).
51. Cancer Drug Coverage Parity Act of 2011, H.R. 2746, 112th Congress (2011).
52. Cancer Treatment Parity Act of 2013, S. 1879, 113th Congress (2013).
53. Cancer Drug Coverage Parity Act of 2013, H.R. 1801, 113th Congress (2013).
54. The Henry J. Kaiser Family Foundation. Health insurance coverage of the total population. 2011-2012. Available from: http://kff.org/other/state-indicator/total-population/. [Accessed April 22, 2014].
55. S.Y. Zafar, J.M. Peppercorn, D. Schrag, and et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18 2013 381 390
56. S.Y. Zafar, and A.P. Abernethy Financial toxicity, part II: how can we help with the burden of treatment-related costs? Oncology (Williston Park) 27 2013 253-4, 256
57. S.Y. Zafar, and A.P. Abernethy Financial toxicity, part I: a new name for a growing problem Oncology (Williston Park) 27 2013 80-1, 149
58. Y.T. Shih, F. Smieliauskas, D.M. Geynisman, and et al. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011 J Clin Oncol 58 33 2015 2190 2196
59. J. Carroll Oral/infusion cancer drug parity begins to raise health plan costs Manag Care 21 2012 7 8
60. Fitch KV, Iwasaki K, Pyenson BS. Parity for oral and intrvenous/injected cancer drugs. Available from: http://us.milliman.com/insight/research/health/Parity-for-oral-and-intravenous/injected-cancer-drugs/. [Accessed December 23, 2013].
61. Loren L, Clemens H, Highland J. Compass Health Analytics Inc. Actuarial assessment of Senate Bill 1070: an act relative to oral cancer therapy. Prepared for Commonwealth of Massachusetts Division of Health Care Finance and Policy.
62. CHBRP. Analysis of Assembly Bill 1000: Cancer Treatment. Report to the 2011-2012 California State Legislature. Available from: http://chbrp.ucop.edu/index.php?action=read&bill-id=125&doc-type=2. [Accessed December 23, 2013].
63. R.G. Frank, K. Beronio, and S.A. Glied Behavioral health parity and the Affordable Care Act J Soc Work Disabil Rehabil 13 2014 31 43
64. B. Wang, S. Joffe, and A.S. Kesselheim Chemotherapy parity laws: a remedy for high drug costs? JAMA Intern Med 174 2014 1721 1722
65. Patient Protection and Affordable Care Act, 42 U.S.C. § 18001 et seq. (2010).
66. ASCO in Action Brief: Value in Cancer Care. 2015. Available from: http://www.asco.org/advocacy/asco-action-brief-value-cancer-care. [Accessed May 17, 2015].
67. D.H. Howard Drug companies' patient-assistance programs - helping patients or profits? N Engl J Med 371 2014 97 99
68. S.B. Streeter, L. Schwartzberg, N. Husain, and et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions J Oncol Pract 7 2011 46s 51s
69. Patient Protection and Affordable Care Act. Public Law 111-148, 42 USC 256a-1, § 1201, March 31, 2010.
70. Howard DH, Bach PB, Berndt ER, et al. Pricing in the market for anticancer drugs. National Bureau of Ecomonic Research Working Paper No. 20867. January 2015. Available from: http://www.nber.org/papers/w20867. [Accessed May 11, 2015].
71. L.J. Howie, and J.M. Peppercorn Polls and policy: signals or substance J Clin Oncol 33 2015 819 820
72. M.A. Socinski, G. Curigliano, I. Jacobs, and et al. Clinical considerations for the development of biosimilars in oncology MAbs 7 2015 286 293
73. Centers for Medicare and Medicaid Services. Oncology care model. Available from: http://innovation.cms.gov/initiatives/Oncology-Care/. [Accessed May 7, 2015].